Na+ CP type Vα Inhibitors
Na+ CP type Vα inhibitors represent a class of chemicals that exert their influence on the Na+ CP type Vα indirectly by targeting various components involved in sodium homeostasis. These inhibitors primarily focus on disrupting sodium channels and transporters, thereby perturbing cellular sodium balance, which intricately regulates the function of Na+ CP type Vα. Amiloride and its derivatives, such as benzamil and dimethyl amiloride, directly block epithelial sodium channels (ENaC), leading to reduced sodium reabsorption in the distal tubules and affecting cellular sodium levels. This disruption in sodium balance indirectly modulates Na+ CP type Vα, given its sensitivity to changes in the cellular environment.
Additionally, other inhibitors like EIPA, mibefradil, and bumetanide target different aspects of ion transport systems, such as sodium-hydrogen exchangers (NHE), T-type calcium channels, and the sodium-potassium-chloride cotransporter (NKCC2). Through their respective actions, these inhibitors influence cellular ion balance, impacting the intricate interplay between sodium regulation and Na+ CP type Vα function. Thiazide diuretics like benzthiazide and indapamide contribute to this modulation by inhibiting sodium reabsorption in the distal tubules, altering cellular sodium concentrations, and indirectly affecting Na+ CP type Vα. Furthermore, carbonic anhydrase inhibitor ethoxzolamide influences intracellular pH, indirectly impacting Na+ CP type Vα, as its function is intricately linked to the cellular milieu. This class of inhibitors offers a nuanced approach to modulating Na+ CP type Vα, demonstrating the intricate connections between sodium homeostasis and the regulation of this specific protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride, a known diuretic, acts as a sodium channel blocker by inhibiting the epithelial sodium channel (ENaC). By directly binding to ENaC, it reduces sodium reabsorption in the distal tubules, thereby impacting the Na+ CP type Vα indirectly through modulation of renal sodium handling. | ||||||
Triamterene | 396-01-0 | sc-213103A sc-213103 | 1 g 5 g | $22.00 $54.00 | ||
Triamterene, a diuretic, acts as a direct inhibitor of the epithelial sodium channel (ENaC). Through its inhibitory action on ENaC, it disrupts sodium reabsorption in the distal tubules, affecting the sodium balance in cells and indirectly modulating the Na+ CP type Vα due to the interplay between sodium channels and cellular sodium levels. | ||||||
5-(N-Ethyl-N-isopropyl)-Amiloride | 1154-25-2 | sc-202458 | 5 mg | $104.00 | 20 | |
EIPA is a selective inhibitor of the sodium-hydrogen exchanger (NHE). By targeting NHE, it disrupts the balance of sodium and hydrogen ions, indirectly impacting the Na+ CP type Vα, as NHE is involved in regulating intracellular pH and sodium concentrations, intricately linked to the cellular environment influencing Na+ CP type Vα function. | ||||||
5-(N,N-Hexamethylene)amiloride | 1428-95-1 | sc-239021 | 25 mg | $100.00 | 2 | |
Hexamethylene amiloride is an amiloride derivative that acts as a potent inhibitor of the epithelial sodium channel (ENaC). Its blockade of ENaC function leads to diminished sodium reabsorption, influencing the cellular sodium milieu and, consequently, indirectly modulating Na+ CP type Vα through the intricate connections between sodium channels and cellular ion balance. | ||||||
Benzthiazide | 91-33-8 | sc-233976 | 1 g | $42.00 | ||
Benzthiazide, a diuretic, acts on the distal tubules to inhibit sodium reabsorption. By influencing sodium balance, it indirectly modulates the Na+ CP type Vα, as sodium levels intricately regulate various cellular processes. Its impact on the sodium balance within cells influences the overall cellular environment, indirectly affecting the function of Na+ CP type Vα. | ||||||
Indapamide | 26807-65-8 | sc-204777 sc-204777A | 250 mg 1 g | $46.00 $64.00 | ||
Indapamide, a thiazide diuretic, inhibits sodium reabsorption in the distal tubules. Through its action on sodium balance, it indirectly influences the Na+ CP type Vα, as sodium levels play a crucial role in cellular homeostasis. The modulation of cellular sodium concentration by indapamide impacts the overall cellular environment, indirectly affecting Na+ CP type Vα function. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $109.00 $228.00 | 9 | |
Bumetanide is a loop diuretic that inhibits the sodium-potassium-chloride cotransporter (NKCC2) in the ascending loop of Henle. By disrupting ion transport in the nephron, it indirectly modulates the Na+ CP type Vα through the intricate connection between renal sodium handling and cellular sodium balance, impacting the overall cellular environment and, consequently, the function of Na+ CP type Vα. | ||||||